Vimpat

RSS

lacosamide

Authorised
This medicine is authorised for use in the European Union.

Overview

Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 24 years and older.

Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Vimpat contains the active substance lacosamide.

This EPAR was last updated on 08/12/2022

Authorisation details

Product details
Name
Vimpat
Agency product number
EMEA/H/C/000863
Active substance
lacosamide
International non-proprietary name (INN) or common name
lacosamide
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX18
Publication details
Marketing-authorisation holder
UCB Pharma SA
Revision
43
Date of issue of marketing authorisation valid throughout the European Union
29/08/2008
Contact address
Allée de la Recherche 60
BE-1070 Brussels
Belgium

Product information

12/10/2022 Vimpat - EMEA/H/C/000863 - N/0098

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antiepileptics

Therapeutic indication

Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating